Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

Lancet

Volumn 358, Issue 9290, 2001, Pages 1322-1327

  Fellay, Jacques ^a   Boubaker, Karim ^a   Ledergerber, Bruno ^b   Bernasconi, Enos ^f   Furrer, Hansjakob ^c   Battegay, Manuel ^d   Hirschel, Bernard ^e   Vernazza, Pietro ^g   Francioli, Patrick ^a,h   Greub, Gilbert ^a   Flepp, Markus ^b   Telenti, Amalio ^a,i  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f Hospital of Lugano   (Switzerland)

^g Hospital of St Gallen   (Switzerland)

^h Swiss HIV Cohort Study Data Center   (Switzerland)

ⁱ UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALKALINE PHOSPHATASE; AMYLASE; BILIRUBIN; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; URATE; ZIDOVUDINE;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; SLEEP DISORDER; TOXICITY; VOMITING;

EID: 0035922595     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06413-3     Document Type: Article

References (17)

1. Management of the adverse effects of antiretroviral therapy and medication adherence
2. Toxicity of antiretroviral agents
3. The case for more cautious, patient-focused antiretroviral therapy
4. Clinical epidemiology and research on HIV infection in Switzerland: The Swiss HIV Cohort Study 1988-2000
5. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
6. Antibiotic induced fatigue
7. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
8. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
9. Stavudine: An update of its use in the treatment of HIV infection
10. Risk of lipodystrophy in HIV-infected patients treated with protease inhibitors: A prospective cohort study
11. Zidovudine: Five years later
12. Hyperlactatemia and antiretroviral therapy: The Swiss HIV Cohort Study
13. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: A phase I trial
14. The didanosine Expanded Access Program: Safety analysis
15. HIV-protease inhibitors
16. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy
17. Durability and reasons for discontinuation of first HAART in a cohort of protease inhibitor naive HIV-infected patients